Evidence map›Paper›PMID 38310584›Full record

Observational studyAdvances in therapy2024

The Association Between Short-Acting β

David Price, Christine Jenkins, Kerry Hancock, Rebecca Vella, Florian Heraud, Porsche Le Cheng, Ruth Murray, Maarten Beekman, Sinthia Bosnic-Anticevich, Fabio Botini and 18 more

Erratum issuedOpen access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Advances in therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Over-the-counter short-acting βNPJ primary care respiratory medicine · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 10 institutions in 5 countries.

David PriceOptimum Patient Care, 5 Coles Lane, Oakington, CB24 3BA, Cambridgeshire, UK. dprice@opri.sg.ORCID 0000-0002-9728-9992
Christine JenkinsThoracic Physician Concord Hospital, Head Respiratory Trials, George Institute, University of Sydney, Sydney, Australia.
Kerry HancockAllergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Level 3, 207 Bouverie Street, VIC, 3010, Australia.
Rebecca VellaOptimum Patient Care Australia, 27 Creek St, Brisbane, QLD, 4000, Australia.
Florian HeraudQueensland Health, Brisbane, QLD, Australia.
Porsche Le ChengOptimum Patient Care Australia, 27 Creek St, Brisbane, QLD, 4000, Australia.
Ruth MurrayOptimum Patient Care, 5 Coles Lane, Oakington, CB24 3BA, Cambridgeshire, UK.
Maarten BeekmanBioPharmaceuticals Medical and Regional Medical Director for International, The Hague, The Netherlands.
Sinthia Bosnic-AnticevichMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.
Fabio BotiniOptimum Patient Care Australia, 27 Creek St, Brisbane, QLD, 4000, Australia.
Victoria CarterOptimum Patient Care, 5 Coles Lane, Oakington, CB24 3BA, Cambridgeshire, UK.
Angelina CatanzaritiAstraZeneca Biopharmaceuticals Medical, Medical Affairs, 66 Talavera Road, Macquarie Park, NSW, Australia.
Joe DoanHealthPlus Medical Centre, 28/26 Belgrave St, Kogarah, NSW, 2217, Australia.
Kirsty FlettonOptimum Patient Care, 5 Coles Lane, Oakington, CB24 3BA, Cambridgeshire, UK.
Ata KichkinBlue Shield Family General Practice, Kogarah, NSW, 2217, Australia.
Thao LeMedical Education, and Events Management Pte Ltd, Singapore, Singapore.
Chantal Le LievreOptimum Patient Care Australia, 27 Creek St, Brisbane, QLD, 4000, Australia.
Chi Ming LauToukley Family Practice, 37-41 Canton Beach Road, Toukley, NSW, 2263, Australia.
Dominique NovicRedlands Medical Centre, 189 Vienna Rd, Alexandra Hills, 4161, Australia.
John PakosWoodcroft Medical Centre, Woodcroft, SA, 5162, Australia.
Kanchanamala RanasingheSchool of Medicine, Griffith University, Gold Coast, Australia.
Alexander RoussosOptimum Patient Care Australia, 27 Creek St, Brisbane, QLD, 4000, Australia.
Josephine Samuel-KingRipponlea Medical Centre, Ripponlea, VIC, 3185, Australia.
Anita SharmaPlatinum Medical Centre, 18 Banfield St, Chermside, QLD, 4032, Australia.
Deb StewartSchool of Medicine, University of Tasmania, Churchill Ave, Hobart, TAS, 7005, Australia.
Bruce WilletVictoria Point Surgery, Brisbane, QLD, 4165, Australia.
Eric BatemanDepartment of Medicine, University of Cape Town, and University Cape Town Lung Institute, Cape Town, South Africa.
OPCA Improving Asthma Outcomes in Australia Research Group
AstraZeneca (Australia) · AUBayside Health Service · AUGriffith University · AUQueensland Health · AURoyal Australian College of General Practitioners · AUThe University of Sydney · AUUniversity of Aberdeen · GBUniversity of Cape Town · ZAUniversity of Tasmania · AUWoolcock Institute of Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn Australia, short-acting β

methodsThis was a cross-sectional study, using data derived from primary care electronic medical records (EMRs) and patient completed questionnaires within Optimum Patient Care Research Database Australia (OPCRDA). A total of 720 individuals aged ≥ 12 years with an asthma diagnosis in their EMRs and receiving asthma therapy were included. The annual number of SABA inhalers authorised on prescription, acquired OTC and reported, and the association with self-reported exacerbations and asthma control were investigated.

results92.9% (n = 380/409) of individuals issued with SABA prescription were authorised ≥ 3 inhalers annually, although this differed from self-reported usage. Of individuals reporting SABA use (n = 546) in the last 12 months, 37.0% reported using ≥ 3 inhalers. These patients who reported SABA overuse experienced 2.52 (95% confidence interval [CI] 1.73-3.70) times more severe exacerbations and were 4.51 times (95% CI 3.13-6.55) more likely to have poor asthma control than those who reported using 1-2 SABA inhalers. Patients who did not receive SABA on prescription (43.2%; n = 311/720) also experienced 2.71 (95% CI 1.07-7.26) times more severe exacerbations than those prescribed 1-2 inhalers. Of these patients, 38.9% reported using OTC SABA and other prescription medications, 26.4% reported using SABA OTC as their only asthma medication, 13.2% were prescribed other therapies but not SABA OTC and 14.5% were not using any medication.

conclusionBoth self-reported SABA overuse and zero SABA prescriptions were associated with poor asthma outcomes. The disconnect between prescribing authorisation, OTC availability and actual use, make it difficult for clinicians to quantify SABA use.

Indexed as

Adrenergic beta-2 Receptor AgonistsAsthmaInappropriate PrescribingAdministration, InhalationAustraliaCross-Sectional StudiesHumansPatient Reported Outcome MeasuresAdrenergic beta-2 Receptor AgonistsAsthma managementAsthma outcomesOver-the-counter medicationPrescription patternsShort-acting β2-agonists

Identifiers

PMID38310584
PMCPMC10879376
OpenAlexW4391521240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.